BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, Wiedenmann B, Roderburg C, Jann H. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci 2019;20:E3049. [PMID: 31234481 DOI: 10.3390/ijms20123049] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 22.3] [Reference Citation Analysis]
Number Citing Articles
1 Castle JT, Levy BE, Chauhan A. Pediatric Neuroendocrine Neoplasms: Rare Malignancies with Incredible Variability. Cancers (Basel) 2022;14:5049. [PMID: 36291833 DOI: 10.3390/cancers14205049] [Reference Citation Analysis]
2 Chen Q, Li Z, Yu J, Xie Q, Lu H, Deng Y, Chen J, Zhu W, Huo L, Zhang Y, Song W, Lan J, Cai J, Huang Z, Wang Z, Zhao H. Novel gold nanoparticles targeting somatostatin receptor subtype two with near-infrared light for neuroendocrine tumour therapy. Nano Res . [DOI: 10.1007/s12274-022-4555-4] [Reference Citation Analysis]
3 Pronin VS, Antsiferov MB, Alexeeva TM, Pronin EV. Targeted treatment with somatostatin analogues: widening horizons of clinical practice. Almanac of Clinical Medicine 2022. [DOI: 10.18786/2072-0505-2022-50-019] [Reference Citation Analysis]
4 Oostveen RF, Kaiser Y, Stroes ES, Verberne HJ. Molecular Imaging of Aortic Valve Stenosis with Positron Emission Tomography. Pharmaceuticals 2022;15:812. [DOI: 10.3390/ph15070812] [Reference Citation Analysis]
5 Shokri S, Johari-daha F, Aghamiri SMR, Karamivand M, Zolghadri S, Yousefnia H. Preparation, quality control, biological evaluation, and human absorbed dose estimation of 188 Re-HYNIC-TOC. Radiochimica Acta 2022;0. [DOI: 10.1515/ract-2021-1125] [Reference Citation Analysis]
6 Börzsei R, Zsidó BZ, Bálint M, Helyes Z, Pintér E, Hetényi C. Exploration of Somatostatin Binding Mechanism to Somatostatin Receptor Subtype 4. IJMS 2022;23:6878. [DOI: 10.3390/ijms23136878] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Li YL, Cheng ZX, Yu FH, Tian C, Tan HY. Advances in medical treatment for pancreatic neuroendocrine neoplasms. World J Gastroenterol 2022; 28(20): 2163-2175 [DOI: 10.3748/wjg.v28.i20.2163] [Reference Citation Analysis]
8 Dai M, Mullins CS, Lu L, Alsfasser G, Linnebacher M. Recent advances in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. World J Gastrointest Surg 2022; 14(5): 383-396 [DOI: 10.4240/wjgs.v14.i5.383] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
9 Syguła A, Ledwon A, Hasse-Lazar K, Jurecka-Lubieniecka B, Michalik B, Paliczka-Cieślik E, Zeman M, Chmielik E, Sczasny J, Jarzab B, Handkiewicz-Junak D. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2022. [PMID: 35503379 DOI: 10.1007/s00259-022-05792-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Alvarez-Villegas D, Giménez-Milà M, Sbraga F, Camprubí I, Gil A. Dealing With the Right Side: Carcinoid Heart Disease. J Cardiothorac Vasc Anesth 2022;36:2228-31. [PMID: 35337745 DOI: 10.1053/j.jvca.2022.02.014] [Reference Citation Analysis]
11 Fortunati E, Argalia G, Zanoni L, Fanti S, Ambrosini V. New PET Radiotracers for the Imaging of Neuroendocrine Neoplasms. Curr Treat Options Oncol 2022. [PMID: 35325412 DOI: 10.1007/s11864-022-00967-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Roden AC, Rakshit S, Johnson GB, Jenkins SM, Mansfield AS. Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors. Front Oncol 2022;12:823667. [PMID: 35198446 DOI: 10.3389/fonc.2022.823667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Heo JH, Choi EJ, Yu SJ, Park YH, Choi JS. Neuroendocrine Tumor with Metachronous Gastrointestinal Stromal Tumor in a Patient: A Case Report. Korean J Gastroenterol 2022;79:72-6. [PMID: 35232922 DOI: 10.4166/kjg.2022.020] [Reference Citation Analysis]
15 Andre A, Squittieri N, Patil S. Evaluating Use of the Octreotide Acetate Pen Injector in a Summative Human Factors Validation Study. Endocr Pract 2022:S1530-891X(22)00034-9. [PMID: 35123070 DOI: 10.1016/j.eprac.2022.01.010] [Reference Citation Analysis]
16 Naik M, Al-Nahhas A, Khan SR. Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides-Where Are We Now. Cancers (Basel) 2022;14:761. [PMID: 35159027 DOI: 10.3390/cancers14030761] [Reference Citation Analysis]
17 Rogoza O, Megnis K, Kudrjavceva M, Gerina-Berzina A, Rovite V. Role of Somatostatin Signalling in Neuroendocrine Tumours. Int J Mol Sci 2022;23:1447. [PMID: 35163374 DOI: 10.3390/ijms23031447] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Patel KR, Nahar A, Elhassan YS, Shetty S, Smith S, Vickrage S, Kemp‐blake J, Palani R, Geh I, Venkataraman H, Shah T, Ayuk J. The effects of somatostatin analogues on glycaemia in the treatment of neuroendocrine tumours. J Neuroendocrinology. [DOI: 10.1111/jne.13064] [Reference Citation Analysis]
19 Fuentes-Fayos AC, G-García ME, Pérez-Gómez JM, Peel A, Blanco-Acevedo C, Solivera J, Ibáñez-Costa A, Gahete MD, Castaño JP, Luque RM. Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance. Int J Mol Sci 2022;23:1143. [PMID: 35163067 DOI: 10.3390/ijms23031143] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Keilin CA, Vankoevering KK, Mchugh JB, Mckean EL. Sinonasal Neuroendocrine Carcinoma: 15 Years of Experience at a Single Institution. J Neurol Surg B Skull Base. [DOI: 10.1055/s-0041-1740968] [Reference Citation Analysis]
21 Feng LH, Su T, Lu Y, Ren S, Huang L, Qin X, Liao T. A model for predicting the overall survival of gastroenteropancreatic neuroendocrine neoplasms after surgery. Scand J Gastroenterol 2022;:1-8. [PMID: 35001789 DOI: 10.1080/00365521.2021.2024247] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Streit L, Moog S, Hugel S, Rame M, Tanguy E, Andry V, Schmid HA, Brunaud L, Bihain F, Nominé-Criqui C, Goumon Y, Lacomme S, Lomazzi S, Vix M, Mutter D, Vitale N, Ory S, Gasman S. Somatostatin analogue pasireotide (SOM230) inhibits catecholamine secretion in human pheochromocytoma cells. Cancer Lett 2022;524:232-44. [PMID: 34637845 DOI: 10.1016/j.canlet.2021.10.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
23 Xie X, Geng C, Li X, Liao J, Li Y, Guo Y, Wang C. Roles of gastrointestinal polypeptides in intestinal barrier regulation. Peptides 2022. [DOI: 10.1016/j.peptides.2022.170753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Chouthai A, Makar M, Sarkar A. Non-surgical Management of Pancreatic Neuroendocrine Tumors (PNETs). Hepato-Pancreato-Biliary Malignancies 2022. [DOI: 10.1007/978-3-030-41683-6_39] [Reference Citation Analysis]
25 Del Olmo-Garcia MI, Prado-Wohlwend S, Andres A, Soriano JM, Bello P, Merino-Torres JF. Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms. Biomedicines 2021;9:1810. [PMID: 34944626 DOI: 10.3390/biomedicines9121810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
26 Tawfik B, Ray D, Moynihan M, Princic N. Costs of treatment change following first-line somatostatin analog monotherapy among patients with neuroendocrine tumors. J Med Econ 2021;24:1337-45. [PMID: 34763589 DOI: 10.1080/13696998.2021.2005374] [Reference Citation Analysis]
27 Xu L, Meng Q, Yao X, Yang R, Zhang P, Li R, Wang F. Dosimetry of 177Lu-DOTATOC first circle treatment in patients with advanced metastatic neuroendocrine tumors: A pilot study in China. Appl Radiat Isot 2022;179:109975. [PMID: 34741954 DOI: 10.1016/j.apradiso.2021.109975] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Alvarez-Villegas D, Giménez-Milà M, Sbraga F, Camprubí I, Gil A, Valchanov K, Shayan H, Castillo J, Weiner MM. Dealing With the Right Side: Carcinoid Heart Disease. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00950-2. [PMID: 34863651 DOI: 10.1053/j.jvca.2021.10.030] [Reference Citation Analysis]
29 Maharjan CK, Ear PH, Tran CG, Howe JR, Chandrasekharan C, Quelle DE. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. Cancers (Basel) 2021;13:5117. [PMID: 34680266 DOI: 10.3390/cancers13205117] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 11.0] [Reference Citation Analysis]
30 Koh TT, Bezak E, Chan D, Cehic G. Targeted alpha-particle therapy in neuroendocrine neoplasms: A systematic review. World J Nucl Med 2021;20:329-35. [PMID: 35018146 DOI: 10.4103/wjnm.wjnm_160_20] [Reference Citation Analysis]
31 Kapralos I, Dokoumetzidis A. Population Pharmacokinetic Modelling of the Complex Release Kinetics of Octreotide LAR: Defining Sub-Populations by Cluster Analysis. Pharmaceutics 2021;13:1578. [PMID: 34683871 DOI: 10.3390/pharmaceutics13101578] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Xu J. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Ther Adv Med Oncol 2021;13:17588359211042689. [PMID: 34484432 DOI: 10.1177/17588359211042689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
33 Andre A, Squittieri N, Patil SB. Evaluation of the Octreotide Acetate Pen Injector and its Instructions for Use in a Formative Human Factors Study. Adv Ther 2021;38:3129-42. [PMID: 33948925 DOI: 10.1007/s12325-021-01739-1] [Reference Citation Analysis]
34 Hijioka S, Morizane C, Ikeda M, Ishii H, Okusaka T, Furuse J. Current status of medical treatment for gastroenteropancreatic neuroendocrine neoplasms and future perspectives. Jpn J Clin Oncol 2021;51:1185-96. [PMID: 34038547 DOI: 10.1093/jjco/hyab076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
35 Chow Z, Johnson J, Chauhan A, Izumi T, Cavnar M, Weiss H, Townsend CM Jr, Anthony L, Wasilchenko C, Melton ML, Schrader J, Evers BM, Rychahou P. PI3K/mTOR Dual Inhibitor PF-04691502 Is a Schedule-Dependent Radiosensitizer for Gastroenteropancreatic Neuroendocrine Tumors. Cells 2021;10:1261. [PMID: 34065268 DOI: 10.3390/cells10051261] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, Ji S. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. Front Endocrinol (Lausanne) 2021;12:679000. [PMID: 34093445 DOI: 10.3389/fendo.2021.679000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
37 Giannetta E, Sesti F, Modica R, Grossrubatscher EM, Guarnotta V, Ragni A, Zanata I, Colao A, Faggiano A. Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers. Front Endocrinol (Lausanne) 2021;12:665698. [PMID: 34093441 DOI: 10.3389/fendo.2021.665698] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
38 Bando-delaunay A, Vaylet De Labriolle C, Keller-petrot I, Lebtahi R. Résultats et perspectives des traitements par Lutathera des tumeurs neuroendocrines à l’hôpital de Beaujon, centre RENATEN. Médecine Nucléaire 2021;45:119-126. [DOI: 10.1016/j.mednuc.2021.01.005] [Reference Citation Analysis]
39 Lima Ferreira J, Marques B, Menke-van der Houven van Oordt CW, de Herder WW, Brabander T, Hofland J. Treatment with somatostatin analogues and PRRT in metastatic middle ear adenoma with neuroendocrine features. Endocrinol Diabetes Metab Case Rep 2021;2021:EDM200172. [PMID: 33982661 DOI: 10.1530/EDM-20-0172] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Patel M, Tena I, Jha A, Taieb D, Pacak K. Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World. Front Endocrinol (Lausanne) 2021;12:625312. [PMID: 33854479 DOI: 10.3389/fendo.2021.625312] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
41 Dearling JLJ, van Dam EM, Harris MJ, Packard AB. Detection and therapy of neuroblastoma minimal residual disease using [64/67Cu]Cu-SARTATE in a preclinical model of hepatic metastases. EJNMMI Res 2021;11:20. [PMID: 33630166 DOI: 10.1186/s13550-021-00763-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
42 Cantone MC, Dicitore A, Vitale G. Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms. J Clin Med 2021;10:501. [PMID: 33535394 DOI: 10.3390/jcm10030501] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
43 Shi D, Dong GQ, Shen KR, Pan Y, Wei SM, Chen Y, Yu RS. Primary cystic and solid neuroendocrine tumor of the retroperitoneum: A case report. Medicine (Baltimore) 2021;100:e24054. [PMID: 33466160 DOI: 10.1097/MD.0000000000024054] [Reference Citation Analysis]
44 Chouthai A, Makar M, Sarkar A. Non-surgical Management of Pancreatic Neuroendocrine Tumors (PNETs). Hepato-Pancreato-Biliary Malignancies 2021. [DOI: 10.1007/978-3-030-37482-2_39-1] [Reference Citation Analysis]
45 Hodge C, Fahy BN. Palliative Interventions for Metastatic Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_19] [Reference Citation Analysis]
46 Rose JB, Zheng-pywell R. Perioperative Management. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_4] [Reference Citation Analysis]
47 Özdirik B, Amthauer H, Schatka I, Goretzki PE, Mogl MT, Fehrenbach U, Tacke F, Jann H, Roderburg C. A rare case of a patient with a high grade neuroendocrine tumor developing neutropenic sepsis after receiving PRRT combined with Capecitabine or Temozolomide: A case report. Mol Clin Oncol 2021;14:20. [PMID: 33363730 DOI: 10.3892/mco.2020.2182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
48 Mele C, Mencarelli M, Caputo M, Mai S, Pagano L, Aimaretti G, Scacchi M, Falchetti A, Marzullo P. Phenotypes Associated With MEN1 Syndrome: A Focus on Genotype-Phenotype Correlations. Front Endocrinol (Lausanne) 2020;11:591501. [PMID: 33312161 DOI: 10.3389/fendo.2020.591501] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
49 Ito T, Jensen RT. Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes. Expert Opin Pharmacother 2021;22:685-93. [PMID: 33131345 DOI: 10.1080/14656566.2020.1845651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
50 Irie Y, Obinata D, Tsukada J, Arakawa S, Kadotani M, Hori Y, Yoshizawa T, Mochida J, Yamaguchi K, Takahashi S. Successful lymphatic embolization using N-butyl-2-cyanoacrylate for postoperative lymphorrhea in a patient with renal pelvic cancer. Radiology Case Reports 2020;15:2139-2143. [DOI: 10.1016/j.radcr.2020.08.051] [Reference Citation Analysis]
51 Ney A, Canciani G, Hsuan JJ, Pereira SP. Modelling Pancreatic Neuroendocrine Cancer: From Bench Side to Clinic. Cancers (Basel) 2020;12:E3170. [PMID: 33126717 DOI: 10.3390/cancers12113170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
52 Klomp MJ, Dalm SU, de Jong M, Feelders RA, Hofland J, Hofland LJ. Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer. Rev Endocr Metab Disord 2021;22:495-510. [PMID: 33085037 DOI: 10.1007/s11154-020-09607-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
53 Ilanchezhian M, Jha A, Pacak K, Del Rivero J. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. Curr Treat Options Oncol 2020;21:85. [PMID: 32862332 DOI: 10.1007/s11864-020-00787-z] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 11.5] [Reference Citation Analysis]
54 Novak D, Tomašič T, Krošelj M, Javornik U, Plavec J, Anderluh M, Kolenc Peitl P. Radiolabelled CCK2 R Antagonists Containing PEG Linkers: Design, Synthesis and Evaluation. ChemMedChem 2021;16:155-63. [PMID: 32643833 DOI: 10.1002/cmdc.202000392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
55 Megdanova-Chipeva VG, Lamarca A, Backen A, McNamara MG, Barriuso J, Sergieva S, Gocheva L, Mansoor W, Manoharan P, Valle JW. Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). Cancers (Basel) 2020;12:E1988. [PMID: 32708210 DOI: 10.3390/cancers12071988] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
56 Sciammarella C, Luce A, Riccardi F, Mocerino C, Modica R, Berretta M, Misso G, Cossu AM, Colao A, Vitale G, Necas A, Fedacko J, Galdiero M, Correale P, Faggiano A, Caraglia M, Capasso A, Grimaldi A. Lanreotide Induces Cytokine Modulation in Intestinal Neuroendocrine Tumors and Overcomes Resistance to Everolimus. Front Oncol 2020;10:1047. [PMID: 32766136 DOI: 10.3389/fonc.2020.01047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
57 Thodou E, Kontogeorgos G. Somatostatin receptor profile in pituitary thyrotroph adenomas. Clin Neurol Neurosurg 2020;195:105865. [PMID: 32416325 DOI: 10.1016/j.clineuro.2020.105865] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
58 Gade AK, Olariu E, Douthit NT. Carcinoid Syndrome: A Review. Cureus. 2020;12:e7186. [PMID: 32257725 DOI: 10.7759/cureus.7186] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
59 Reynaert H, Colle I. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature. Int J Mol Sci 2019;20:E4811. [PMID: 31569719 DOI: 10.3390/ijms20194811] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]